RxDoctor Payments Data

Kate Mount

Nurse Practitioner · Mobile, ALNPI 1629513023

Payments from drug & device makers

$3,880in general payments, 2019–2025

Across 205 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$836
  • Actelion Pharmaceuticals US, Inc.$478
  • Pfizer$477
  • Scpharmaceuticals Inc.$472
  • Boehringer Ingelheim$450
  • Johnson & Johnson$303
  • plus $863 from 12 others

What the payments were for

  • Food & beverage$3,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,880 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$53,806
Medicare patients
444
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban397$348,565
EntrestoSacubitril/Valsartan132$125,300
XareltoRivaroxaban83$84,494
FarxigaDapagliflozin Propanediol49$46,380
JardianceEmpagliflozin33$38,830
BrilintaTicagrelor39$28,947
Repatha SureclickEvolocumab33$25,164
Ranolazine ErRanolazine191$16,126
Ezetimibe217$5,720
Flecainide Acetate94$4,720
Amiodarone Hcl216$4,206
Rosuvastatin Calcium280$4,095
ClopidogrelClopidogrel Bisulfate361$3,869
Atorvastatin Calcium338$3,578
Midodrine Hcl55$3,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$477$348,565397 claims
NovartisEntresto$836$125,300132 claims
Johnson & JohnsonXarelto$303$84,49483 claims
AstraZenecaFarxiga, Brilinta$156$75,32688 claims
Boehringer IngelheimJardiance$450$38,83033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →